Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST)

Phase 4 Completed 70 enrolled Duke University GlaxoSmithKline · collab Kibongoto National Tuberculosis Hospital, Tanzania · collab Kilimanjaro Christian Medical Centre, Tanzania · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is twofold: (1) to assess the feasibility and safety of fixed dose combination zidovudine/lamivudine/abacavir in HIV infected subjects with tuberculosis in a resource-limited setting, and (2) to assess the impact of delayed versus early initiation strategies for fixed dose combination zidovudine/lamivudine/abacavir on the rate of tuberculosis-associated immune reconstitution inflammatory syndromes.

Timeline

Start: 2004-06
Primary completion: 2007-09
Completion: 2007-09

Publications

Results Shao HJ, Crump JA, Ramadhani HO, Uiso LO, Ole-Nguyaine S, Moon AM, Kiwera RA, Woods CW, Shao JF, Bartlett JA, Thielman NM. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. AIDS Res Hum Retroviruses. 2009 Dec;25(12):1277-85. doi: 10.1089/aid.2009.0100.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abacavir	Other / unclassified	300 mg	Oral
Subject	Lamivudine	Other / unclassified	150 mg	Oral
Subject	Zidovudine	Small molecule	300 mg	Oral

Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST)

Summary

Timeline

Publications

Drugs

Indications